Soligenix, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2013. Soligenix is a clinical-stage biopharmaceutical company developing therapies for inflammatory diseases and biodefense products, organized into BioTherapeutics and Vaccines/BioDefense segments. Revenue was principally from NIH grants, not product sales.
Financial results and position
| Metric | Q1 2013 | Q1 2012 / prior period |
|---|---|---|
| Grant revenue | $900,354 | $647,418; up 39% |
| Cost of revenues | $743,657 | $556,571 |
| Gross profit and margin | $156,697; 17.4% | $90,847; 14.0% |
| Research and development | $756,653 | $876,794; down 14% |
| General and administrative | $487,941 | $655,043; down 26% |
| Operating loss | $(1,087,897) | $(1,440,990) |
| Net loss / loss per share | $(1,087,414) / $(0.10) | $(1,438,755) / $(0.13) |
| Cash used in operations | $(744,359) | $(675,535) |
| Cash and cash equivalents | $2,612,021 at March 31 | $3,356,380 at December 31, 2012 |
| Working capital | $1,763,848 at March 31 | $2,682,383 at December 31, 2012 |
Assets totaled $4.25 million and shareholders’ equity was $2.58 million at quarter-end. Current liabilities were $1.68 million, consisting of accounts payable and accrued compensation; the balance sheet reports no debt. The filing reports no income tax provision, reflecting losses and a full valuation allowance against deferred tax assets.
Changes and operating context
- Net loss narrowed 24%, reflecting higher grant revenue and lower R&D and G&A costs. Management attributed expense reductions chiefly to reduced headcount, allocation of employee costs to grants, and lower outside professional services.
- Cash used in operations increased 10% year over year despite the lower net loss. Cash declined 22% from year-end, and working capital declined 34%.
- Grant revenue was $829,849 for Vaccines/BioDefense and $70,505 for BioTherapeutics. The company said approximately $3.6 million of active grant funding remained available for associated programs.
- During the quarter, Soligenix issued 26,063 shares to vendors for services. At March 31, 11,194,968 common shares were outstanding; 12,231,492 were outstanding as of May 1.
Outlook, risks and unusual items
- Management estimated that cash, grant proceeds and expected New Jersey tax-certificate proceeds would fund working capital and capital expenditures into the second quarter of 2014. This is dependent on expected funding and collections; the company said it may seek additional equity financing and cannot assure favorable terms or completion.
- For the next 12 months, the company projected approximately $3.4 million in R&D spending before grant reimbursements and approximately $3.1 million in grant revenue to offset R&D costs.
- Clinical plans included SGX203 pediatric Crohn’s disease trials, a planned Phase 2 SGX942 oral-mucositis trial, and further development of orBec, RiVax, VeloThrax and OrbeShield. Timelines and outcomes are forward-looking and subject to clinical, regulatory and funding risks.
- Soligenix submitted a proposal to BARDA in February 2013 for a potential OrbeShield development contract and expected a response in the second half of 2013. No award was reported in this filing.
- On April 27, 2013, after quarter-end, the company issued Intrexon 1,034,483 shares—about 8.5% of then-outstanding common shares—in exchange for an exclusive channel agreement to use Intrexon technologies for a new biodefense and infectious-disease application.
- Licensing-related commitments were approximately $368,800, with potential milestone and royalty payments contingent on clinical or commercial success. Total disclosed contractual obligations over five years were $574,100, including leases.
- Principal risks include clinical and regulatory failure, dependence on government grants and other funding, limited cash resources, potential dilution from equity financing, intellectual-property and commercialization risks, and the possibility that anticipated contracts or milestones do not occur. The company reported disclosure controls effective at a reasonable-assurance level and no additional risk factors beyond those in its 2012 Form 10-K.
Important facts for investors to verify
- Whether grants are renewed or additional funding is secured, and whether cash runway remains consistent with management’s estimate.
- Progress, enrollment and results for planned clinical trials, particularly SGX203 and SGX942, and regulatory status of the programs.
- Whether BARDA or other government agencies award contracts, and the timing and conditions of any such funding.
- The impact of the Intrexon share issuance and any further equity compensation or financing on the share count and existing investors.
- Reconcile management’s stated program timelines with subsequent disclosures; the filing’s product-development table includes dates and milestones that may require confirmation against later company updates.